Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In a 48-week, placebo-controlled phase-2 trial (338 participants) reported by Lilly, the highest dose achieved a mean weight reduction of 24.2% (about 57.8 lb) at the end of treatment
Published findings are primarily preclinical and exploratory, and all materials are intended for research use only
Other entero-pancreatic hormones and combination of entero-pancreatic hormones in the management of obesity Numerous entero-pancreatic hormones [GIP, glucagon, amylin and peptide YY (PYY) agonists and GIP antagonists] with diverse metabolic actions are currently under investigation either alone or in combination with GLP-1 RA (Fig
No cases of drug-induced liver injury or sustained elevation in liver enzymes were reported in either study
